CN102614407A - Chinese medicinal composition for treating postpartum depression - Google Patents
Chinese medicinal composition for treating postpartum depression Download PDFInfo
- Publication number
- CN102614407A CN102614407A CN2012101199831A CN201210119983A CN102614407A CN 102614407 A CN102614407 A CN 102614407A CN 2012101199831 A CN2012101199831 A CN 2012101199831A CN 201210119983 A CN201210119983 A CN 201210119983A CN 102614407 A CN102614407 A CN 102614407A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- medicine composition
- postpartum depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 201000009916 Postpartum depression Diseases 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 68
- 239000004863 Frankincense Substances 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims description 18
- 210000000582 semen Anatomy 0.000 claims description 13
- 241000717739 Boswellia sacra Species 0.000 claims description 12
- 241000283956 Manis Species 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 5
- 235000011438 Albizia odoratissima Nutrition 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 241000220433 Albizia Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 210000004185 liver Anatomy 0.000 abstract description 21
- 238000002360 preparation method Methods 0.000 abstract description 10
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- 210000000952 spleen Anatomy 0.000 abstract description 8
- 210000002784 stomach Anatomy 0.000 abstract description 8
- 210000005036 nerve Anatomy 0.000 abstract description 7
- 230000003213 activating effect Effects 0.000 abstract description 4
- 241000427159 Achyranthes Species 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 abstract 1
- 235000017491 Bambusa tulda Nutrition 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 235000008671 Calycanthus floridus Nutrition 0.000 abstract 1
- 235000008670 Calycanthus occidentalis Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 244000148992 Lindera benzoin Species 0.000 abstract 1
- 235000004520 Lindera benzoin Nutrition 0.000 abstract 1
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000008866 Ziziphus nummularia Species 0.000 abstract 1
- 239000011425 bamboo Substances 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 210000002435 tendon Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 230000009182 swimming Effects 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 7
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 7
- 229960003147 reserpine Drugs 0.000 description 7
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 229940023488 pill Drugs 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 241000581650 Ivesia Species 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010022998 Irritability Diseases 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 206010043458 Thirst Diseases 0.000 description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008531 Chills Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 230000035568 catharsis Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000000559 Albizia odoratissima Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000037047 psychomotor activity Effects 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 230000036259 sexual stimuli Effects 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- -1 suspensoid Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for treating postpartum depression, and relates to the technical field of traditional Chinese medicine. The Chinese medicinal composition is prepared from the following raw materials in parts by weight: 2-3 parts of seed of wild jujube, 1-2 parts of rehmannia root, 1-2 parts of bamboo leaf, 0.5-2 parts of frankincense, 2-3 parts of angelica, 1-3 parts of bupleurum, 2-3 parts of root of three-nerved spicebush, 2-3 parts of cortex albiziae, 0.5-1 part of pangolin, 1-2 parts of szechuan lovage rhizome and 1-2 parts of root of bidentate achyranthes. The Chinese medicinal composition provided by the invention has the characteristics of obvious curative effect, short treatment period, quick response and obvious treatment effect, has the effects of relieving liver for smooth qi, clearing heat and relieving fidgetness, astringing qi and soothing the nerves, regulating the character of liver, nourishing tendons and marrow, and harmonizing stomach and activating spleen, and has the advantages of simple preparation process and low raw material cost.
Description
Technical field
The present invention relates to the Chinese medicine technical field, be specifically related to a kind of Chinese medicine composition of treating postpartum depression.
Background technology
Postpartum depression also is postpartum depression, be women puerperal because physiology and psychological factor cause, and symptom has anxiety, doubt, compunction, fear etc., only a few is serious has despair, run away from home, injure the idea and the action of child or suicide.
Postpartum depression is a type the most common in women's mental disorder, is that women's puerperal is because a series of variations such as the health that gonadal hormone, social role and mental change are brought, emotion, psychology.Typical postpartum depression is to take place in 6 weeks of puerperal, sustainable whole puerperal, have in addition continue to the child and go to school before.The sickness rate of postpartum depression is 15%～30%, and gestation then has 20%～30% relapse rate once more.Research shows that the women of 50-75% will be along with one section " Baby blues " (postpartum depression) of birth experience of child, and most women's signs are not obvious or written in water, occur one section unstable emotion in character, and are not good enough like not bright sobbing or mind.The psychiatric department expert of hospital of the National Defence University of PLA points out that the new mother of 10-15% becomes very strong in this situation, and its attribution is a kind of disease, and this is up-to-dately to be recognized by medical circle, and is called the disease of " postpartum depression " by buzzword.
At present, tricyclic antidepressant is as a line medicine of treatment depression, and second filial generation atypia antidepressants are the second line medicine.Various tricyclic antidepressant curative effects are equally matched, clinical can the selection according to depression and sedation power, side effect and patient's tolerance situation.A little less than imipramine and the desmethylimipramine sedation, be applicable to the depressive patient that psychomotor activity is sluggish.Amitriptyline, doxepin sedation are stronger, applicable to anxiety, intense and insomniac.But tricyclic antidepressants medicine anticholinergic and cardiovascular side effects are bigger.Second filial generation atypia antidepressant kind is a lot, and with selectivity 5-HT reuptake inhibitor fluoxetine, paroxetine, Sertraline, its application is wider, and side effect is little, and security performance is better, utilizes the long term maintenance treatment.
Because the Western medicine toxic and side effects is strong, especially, can influence neonatal health simultaneously to women breast-feeding their children.The relevant report that adopts the therapy of combining Chinese and Western medicine postpartum depression is arranged at present; As adopt acupuncture to add the western medicine postpartum depression; To observe the clinical efficacy (Li Yanping of dadingfengzhu pill plus-minus treatment postpartum depression in addition; Dadingfengzhu pill treatment postpartum depression 38 routine observation of curative effect, " Chinese medicine academic periodical " 2005 23 8 phases of volume).Chinese medicine is discussed less to the special piece of writing of postpartum depression, consider the physiological characteristics of multiple deficiency and stasis in puerperal, and postpartum depression is divided into blood deficiency gas weak type, and deteriorated blood stops long-pending type; The type of deficiency of both the heart and spleen opinion is controlled (Liu Minru, Tan Wanxin chief editor, the senior book series of Chinese medicine and pharmacy " traditional Chinese obstetrics and gynecology "; And Zhang Yuzhen etc. have increased hepatic depression combined symptoms type (Zhang Yuzhen chief editor Beijing: People's Health Publisher, October calendar year 2001); The whole nation high Chinese medicine universities and colleges planning teaching material " Gynecology of Chinese Medicine ", Beijing: China Traditional Chinese Medicine Publishing House, in JIUYUE, 2002); Treatment is a well-established law with the tonify deficiency blood stasis dispelling, through clinical verification for many years, has obtained satisfied clinical efficacy.The Chinese medicine postpartum depression can under instruction of Chinese Medicine theory, be carried out dialectical executing and control according to clinical concrete symptom, Chinese medicine composition of the present invention when the treatment postpartum depression from whole, internal organs, from the source of disease, dialectical ask because of, examine because of discussing and control.
Summary of the invention
The invention provides a kind of pharmaceutical composition of treating postpartum depression and preparation method thereof.
A kind of pharmaceutical composition of treating postpartum depression of the present invention is processed by following raw medicaments in portion by weight: Semen Ziziphi Spinosae 2-3 part, Radix Rehmanniae 1-2 part, Folium Bambusae 1-2 part, Olibanum 0.5-2 part, Radix Angelicae Sinensis 2-3 part, Radix Bupleuri 1-3 part, Radix Linderae 2-3 part, Cortex Albiziae 2-3 part, Squama Manis 0.5-1 part, Rhizoma Chuanxiong 1-2 part, Radix Achyranthis Bidentatae 1-2 part.
Preferably, Chinese medicine composition of the present invention is to be processed by the raw material of following weight parts: 3 parts of Semen Ziziphi Spinosaes, 2 parts of Radix Rehmanniae, 1 part on Folium Bambusae, 0.5 part of Olibanum, 2 parts of Radix Angelicae Sinensis, 2 parts of Radix Bupleuri, 2 parts of the Radixs Linderae, 3 parts of Cortex Albiziaes, 0.5 part of Squama Manis, 2 parts of Rhizoma Chuanxiongs, 1 part of Radix Achyranthis Bidentatae.
Side of the present invention separates: Semen Ziziphi Spinosae in the prescription of the present invention: nature and flavor: sweet, flat.Gui Jing: heart channel; Spleen channel; Liver Channel; Gallbladder meridian.Function: mind tranquilizing and the heart calming; Nourishing the liver; Arresting sweating.Cure mainly: deficiency of YIN-blood, severe palpitation, insomnia forgetfulness; The empty hyperhidrosis of body." herbal classic ": main trusted subordinate's cold and heat, pathogens agglomerating gas gathers, painful limbs, arthralgia chiefly caused by damp pathogen." not Lu ": main vexatious insomnia, umbilicus is pain up and down, and blood changes chronic diarrhea, the sweating due to debility excessive thirst, invigorating middle warmer, the liver benefiting gas, hard muscles and bones is helped cloudy gas, makes us fertile strong." property of medicine opinion ": main muscles and bones wind, fry the end and make the soup clothes." book on Chinese herbal medicine converges and says ": astringing QI is calmed the nerves, and flourish muscle is supported marrow, stomach function regulating activating the spleen." book on Chinese herbal medicine is new again ": suppressing the hyperactive liver is regulated the flow of vital energy, nourishing lung-YIN, and the warming middle-JIAO dampness removing, the astringing QI hidroschesis, beneficial will is breathed out surely, hearing-improing and eyesight improving.
Radix Rehmanniae: sweetness and bitterness, cold." herbal classic ": " sweet in the mouth; Cold." " not Lu " " hardship, nontoxic." go into the heart, liver, kidney channel.Effect, the clearing away heat and promoting production of body fluid YIN nourishing is nourished blood.Cure mainly and control fever due to yin deficiency, quench one's thirst, spit blood, epistaxis, metrorrhagia, menoxenia, frequent fetal movement, the moon is hindered constipation.
Folium Bambusae: the property slightly sweet flavor, cold." book on Chinese herbal medicine just ": slightly sweet flavor, gas is put down little cold.Gui Jing goes into the heart, lung, gallbladder, stomach warp.Clearing heat and relieving fidgetness, the diuresis of promoting the production of body fluid.Control the calentura excessive thirst, pediatric epilepsy scared, cough with dyspnea is told nosebleed, flushed complexion, oliguria also, the erosion of the oral mucosa tongue boil." not Lu ": the main heat of expectorant in the heart, cough with dyspnea." property of medicine opinion ": main haematemesis pyretic toxicity wind, only quench one's thirst." Treatise on Dietetic Therapy ": main cough with dyspnea, quench one's thirst phlegm retention, sore throat, heat clearing away and restlessness relieving." Japan hanako materia medica ": expectorant, control fanatical unhappiness, apoplectic aphasia in silence, high fever, headache wind syndrome of head, and cherish the pregnant number of people and revolve and fall down to the ground, spasmolytic is throbbed with fear, the pestilence fan is vexed, the pediatric epilepsy scared sky hangs.Zhang Yuansu: cool heart channel, beneficial vigour, heat extraction, slow spleen." book on Chinese herbal medicine is just ": the irritated sleeplessness of reducing the asthenic fever, end excessive thirst, born fluid, Li Xiaoshui separates sore throat, and the children's wind-heat infantile convulsion.
Olibanum: the treating blood disorders blood circulation promoting and blood stasis dispelling, pain relieving, the warm heart, regulating qi and activating blood, analgesic therapy chases after poison.Control coagulation of QI-blood, trusted subordinate's pain, carbuncle pyogenic infections from tumour or sore, traumatic injury, dysmenorrhea, postnatal blood stasis twinge.
Radix Angelicae Sinensis: formal name used at school Angelica sinensis, herbaceos perennial is enriched blood and invigorates blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.Be used for blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.Have anti-hypoxia, anticancer, improve looks, enrich blood invigorate blood circulation, effect such as antibacterial, arteriosclerosis.The Japan scholar reports that Japanese Taihe county Radix Angelicae Sinensis (An-gelicaacutilobaKitagalia) volatile oil has effects such as calmness, hypnosis, analgesia, anesthesia.
Radix Bupleuri: return Liver Channel, gallbladder meridian.Function: evacuate and bring down a fever the yang invigorating soothing liver-QI.Cure mainly: cold, fever, alternate attack of chill and fever, malaria, stagnation of QI due to depression of the liver, sternal rib pain, proctoptosis, the uterus comes off, menoxenia." book on Chinese herbal medicine is just ": Radix Bupleuri, cool diffusing with this person with it, the heat of suppressing the hyperactive liver.It is cool in nature, thus separate alternate attack of chill and fever, flesh table hectic fever, the liver and gall fire is scorching, the chest and hypochondrium knot, the double skin infection of controlling, the blood chamber is heated; Its property is loose, so main typhoid fever pathogenic heat are not separated epidemic febrile disease intenseness of heat, SHAO YANG headache, Liver Channel melancholia.
The Radix Linderae: suffering, temperature.Return lung, spleen, kidney, urinary bladder channel.Promoting the circulation of QI to relieve pain, warming kidney for dispelling cold." medicineization justice ": the Radix Linderae, the male temperature of gas so fast gas a surname is logical, is evacuated and is stagnated, and is far more than Rhizoma Cyperi.Induce sweat outward and manage flesh, interior alleviating distention in middle-JIAO and pleasant.With cold expelling gas, then the cold pain of visitor is from removing; The gas of getting rid of evils is then gone the epidemic disease miasma promptly but in the sky; Dissipating depression of QI gas, attacked by pestiferous factors stomachache, the chest and diaphragm distension can subtract suddenly; Dredge through gas, the apoplexy extremity are unsuccessful, and the primiparity vim and vigour stagnate, and can lead to gradually, and all the merit of its gas hero of mat also.
Cortex Albiziae: Cortex Albiziae is the dry bark of leguminous plant Herba Albiziae, and nature and flavor are sweet, flat.The merit that resolving depression and blood, mind calming, subduing inflammation are arranged.The effect that the irritability of controlling, melancholy, insomnia, lung abscess, carbuncle, scrofula, muscles and bones folding wound are arranged.
Squama Manis: salty in the mouth; Cold nature is returned liver, the stomach warp.Cure mainly: blood circulation promoting and dispersing pathogen accumulation; The stimulating milk secretion of stimulating the menstrual flow; Eliminating carbuncle is burst hard.Main blood stasis amenorrhea; Lump in the abdomen; Rheumatic arthralgia; Agalactia.
Rhizoma Chuanxiong: another name Rhizoma Chuanxiong (" book on Chinese herbal medicine "), blood-activating and qi-promoting, wind-expelling pain-stopping; Be used to pacify nerve, positive wind syndrome of head headache, lump in the abdomen stomachache, the twinge of the breast side of body, tumbling and swelling, headache, rheumatic arthralgia; For medicine first choice of the treatment headache, be the monarch drug among the we.Modern medicine and pharmacology discovers that Rhizoma Chuanxiong has tangible sedation.Movable inhibited to animal brain when Rhizoma Chuanxiong volatile oil is a small amount of, and medulla oblongata respiratory center, vasomotor center and spinal reflex maincenter are had excitation.In vitro testses such as antibacterial action show that Rhizoma Chuanxiong has inhibitory action to large intestine, dysentery (Song Nei Shi), distortion, green pus, typhoid fever, Salmonella paratyphi and vibrio cholera etc.
Radix Achyranthis Bidentatae: bitter, sour, property is put down; Invigorating the liver and kidney, bone and muscle strengthening, promoting blood circulation to restore menstrual flow, ignite (blood) is descending, inducing diuresis for treating stranguria syndrome; Be used for soreness of waist and knee joint; Flaccidity and weakness of the lower limbs; Amenorrhea due to stagnation of blood; Dysmenorrhea; Puerperal abdominal pain due to blood stasis; Lump in the abdomen; Retention of placenta; Pyretic stranguria; Stranguria with blood; Traumatic injury; The carbuncle malignant boil; Laryngopharynx swelling and pain.
The traditional Chinese medical science thinks, the main pathogenesis of depression is because feelings will is hindered, and due to depression of liver-QI causes that gradually the five internal organs mechanism of qi gets along well, but mainly is liver, spleen, and the heart three is dirty gets involved and disorder of QI and blood forms.Postpartum hemorrhage makes in the essence and blood and loses, and the five internal organs lose in moistening foster, and is moving in the fire of five will, disturbing the mind upwards; Depression of liver-QI so that depressed in addition cries that it is not normal to laugh at, and is depressed few joyous; Stagnation of QI due to depression of the liver, catharsis dereliction of duty, on must not help cardiopulmonary with qi and blood circulation promotion; In can not help taste with department's fortuneization, be difficult to sharp three warmers and unclog the channel, thus cause gloomy be tired of bloated.It is congenital that the women is called usually with liver, is this with blood, is usefulness with blood.QI and blood took off and let out puerperal, the essence and blood consume, and liver is lost and nourishes, and then the not normal feelings will that causes of catharsis is not smooth, being about to cry due to sadness, sigh uncomfortable in chest, milk reduces, and the menses imbalance forms the card of stagnation of liver-QI.
Chinese medicine composition of the present invention is collaborative each other, and the effect that can play " monarch " altogether is main with soothing the liver nourishing blood, and assistant is with the clearing heat and relieving fidgetness of calming the nerves.We are with 5 usefulness such as Radix Angelicae Sinensis, the Radix Linderae, Olibanums; Play the effect of promoting flow of QI and blood, cold expelling antalgic altogether, be equipped with depressed liver-energy dispersing and QI regulatingization such as Radix Bupleuri, Radix Achyranthis Bidentatae, Squama Manis, Radix Rehmanniae and stagnate the Fructus Alpiniae Oxyphyllaes of calming the nerves such as Semen Ziziphi Spinosae, Cortex Albiziae, Rhizoma Chuanxiong; Strongly fragrant heat-transformation of a specified duration is with the relieving restlessness that clears away heart-fire such as Semen Ziziphi Spinosae, Folium Bambusae.We's characteristics: the one, nourish blood and transfer irritability blood to rule together, the 2nd, the easing the affected liver Ning Zhi that calms the nerves; Then QI and blood is full along reaching for irritability, and all diseases are then removed.
Confirm that Chinese medicine composition of the present invention is for a long time oral safely, have no side effect through animal acute toxicity test and long term toxicity test.
Chinese medicine composition pharmacodynamics test of the present invention shows that the chronic unpredictability depression model of mice is had therapeutical effect.Compare with the blank group, the dead time of the shortening forced swimming mice that Chinese medicine composition of the present invention can be in various degree, weight of mice is slow, and medicine does not have obvious influence to mice body constitution; It is comparatively obvious to reduce the mice dead time, demonstrates stronger antidepressant effect.
The present invention is through system keeps track and observation to 200 routine postpartum depression patients in addition, and its total effective rate is 98.0 %, wherein, cures 160 examples, accounts for 80%; Significantly improvement 20 examples account for 10%; 16 examples that take a turn for the better account for 8%, and invalid 4 examples account for 2%.
Chinese medicine preparation of the present invention; Preparation technology is simple; When being prepared into medicament, can add the medicine acceptable carrier, said medicine acceptable carrier can be but be not limited to: starch, sucrose, lactose, mannitol, silicon derivative, cellulose family and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, cyclodextrin, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Chinese medicine preparation of the present invention can be any pharmaceutically useful dosage form, and these dosage forms include but not limited to: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, buccal tablet, granule, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.
Preparation of the present invention, preferred Chinese medicine preparation is a peroral dosage form, as: tablet, capsule, oral liquid, buccal tablet, granule, pill, powder, suspensoid, powder, solution, drop, drop pill.
Preferred Chinese medicine preparation is capsule, tablet or granule.
Most preferably be capsule.
The concrete method for preparing of capsule of the present invention is following:
A, according to the present invention prescription, take by weighing raw medicinal material Semen Ziziphi Spinosae, Radix Rehmanniae, Folium Bambusae, Olibanum, Radix Angelicae Sinensis, Radix Bupleuri, the Radix Linderae, Cortex Albiziae, Squama Manis, Rhizoma Chuanxiong, the Radix Achyranthis Bidentatae of recipe quantity; Clean, dry;
B, with above-mentioned pulverizing medicinal materials, cross 80 mesh sieves, behind ultraviolet-sterilization, insert capsule No. 0, promptly get.
Chinese medicinal capsule of the present invention, cheap, usage is simple: the consumption of each 2.0-4.0g, every day 2-3 time.
Chinese medicine composition of the present invention in addition also can water is fried be taken.
Chinese medicine composition pharmacodynamic study of the present invention
1, irritates the configuration and the administration of stomach medicinal liquid
Get the medicine of embodiment 1,2,3, be assigned to the 0.2g/ml suspension with the normal saline that contains 2% Radix Acaciae senegalis, low tempertaure storage below 10 ℃, subsequent use.The gastric infusion mode is adopted in experiment.
The preparation of positive control drug: get 4 of fluoxetine tablets (25mg/ sheet), be made into the medicinal liquid of 2mg/ml, be positive controls with the 50ml redistilled water.
2, the compound recipe pharmacodynamics of different proportionings is estimated
Table 1 divides into groups and administration 2.1 laboratory animal pressed, and 9:00～10:00 irritates stomach once, continuous irrigation stomach 14 days morning every day.
Table 1 laboratory animal is divided into groups and dosage regimen
| The group numbering | Group | Number of animals | Dosage |
| 1 | Blank group (distilled water) | 10 | 0.1ml/10g |
| 2 | Positive controls (fluoxetine) | 10 | 5.0g/kg |
| 3 | The proportioning of embodiment 1 | 12 | 1.0.g/kg |
| 4 | The proportioning of embodiment 1 | 12 | 2.0g/kg |
| 5 | The proportioning of embodiment 1 | 12 | 4.0g/kg |
| 6 | The proportioning of embodiment 2 | 12 | 1.0g/kg |
| 7 | The proportioning of embodiment 2 | 12 | 2.0g/kg |
| 8 | The proportioning of embodiment 2 | 12 | 4.0g/kg |
| 9 | The proportioning of embodiment 3 | 12 | 1.0g/kg |
| 10 | The proportioning of embodiment 3 | 12 | 4.0g/kg |
| 11 | The proportioning of embodiment 4 | 12 | 2.0g/kg |
| 12 | The proportioning of embodiment 5 | 12 | 2.0g/kg |
2.2 mouse tail suspension experiment: laboratory animal is pressed table 1 divide into groups and administration continuous irrigation stomach 14 days.1h after the last administration is attached to the part at mouse tail l-2cm place on the one horizontal waddy, makes animal become the reversal of the natural order of things state, and the about 20cm of its head destage face separates the animal sight line with cardboard all around.Observe 6min, and, be the disappointed time with dead time of mice in the stopwatch record back 4min.
2.3 the experiment of mice forced swimming: dosage regimen is the same, and 1h experimentizes after the last administration.(promptly the 13rd day) mice training swimming 6min tests behind the 24h: mice is put into depth of water 10cm drink 5000ml beaker (high 20cm, diameter 14cm), 25 ± 2 ℃ of water temperatures before the experiment.Observe 6min, relatively each organizes the dead time of mice in the 4min of back to record.
2.4 the judgment criteria of the motionless behavior of animal: the judgment criteria of the motionless behavior of animal is that mouse head is downward in the outstanding tail experiment, and extremity are sagging naturally, and back is not crooked to both sides.The mice forelimb have a little move still be regarded as motionless.In the forced swimming experiment, the little volume body of mice, head exposes, but keeps the aggregate level posture to float on the water surface, is the dead time.
2.5 the mouse temperature that the antagonism reserpine brings out reduces experiment: animal grouping and dosage regimen are the same.Body temperature is measured and is adopted the digital electronic clinical thermometer.In advance embrocate electronic clinical thermometer with a little silicone oil, make it lubricated, thermometer probe is inserted mice anus l-2cm gently, record reading after the temperature demonstration is stable is as basal body temperature.Irritate stomach afterwards and give relative medicine, 1h pneumoretroperitoneum administration reserpine injection 2.5mg/kg measured body temperature respectively then after 1,4,24 and 48 hour, with body temperature reduction value (△ T=T basis-T) as index, carry out statistical analysis.
3 statistical analysis
Data are represented with the form of means standard deviation.Adopt the one factor analysis of variance method to carry out statistical analysis.Data are by the SPSS software processes, p 0. 05 have significant difference, or p < 0. 01 have utmost point significant difference.
4 interpretations of result
This experiment gained data are represented with the form of means standard deviation.Data are by the SPSS software processes, p 0. 05 have significant difference, or p < 0. 01 have utmost point significant difference.Statistical content comprises in the outstanding tail experiment in mice dead time, the experiment of mice forced swimming that mice inner directed behavior number of times and antagonism reserpine bring out mouse temperature in dead time, the barnyard experiment and reduces amplitude.
4.1 the mice body weight detects
Each organizes mice the 1st, 5, and 10 days body weight statistics is seen table 3.The result shows, mice body weight there are no significant difference between each group, and the amplitude of body weight change and trend are comparatively random, explain that medicine does not have obvious influence to mice body constitution.
Table 2 mice body weight monitor value (g) (x ± S)
| The group numbering | First day | The 5th day | The tenth day |
| 1 | 22.88±2.12 | 25.21±1.71 | 25.22±3.49 |
| 2 | 22.40±2.19 | 23.02±2.81 | 25.13±2.09 |
| 3 | 23.10±2.01 | 24.01±2.06 | 25.02±3.01 |
| 4 | 22.94±3.02 | 24.19±2.14 | 23.74±2.24 |
| 5 | 22.40±1.84 | 25.61±1.70 | 22.28±1.89 |
| 6 | 22.60±2.01 | 24.32±2.14 | 26.03±2.16 |
| 7 | 22.66±2.22 | 21.49±3.86 | 23.02±2.22 |
| 8 | 22.09±3.01 | 23.02±1.88 | 24.53±3.16 |
| 9 | 22.58±2.60 | 23.81±2.76 | 23.22±3.01 |
| 10 | 22.64±2.88 | 25.02±3.81 | 23.53±2.06 |
| 11 | 22.97±1.87 | 22.41±3.76 | 25.34±3.44 |
| 12 | 23.24±3.22 | 25.12±3.08 | 25.03±3.16 |
4.2 Chinese medicine composition of the present invention is to the influence of forced swimming mice dead time
Each is organized mice non-swimming time result and sees table 3.
Table 3 Chinese medicine composition of the present invention is to the influence of mice forced swimming experiment dead time (x ± s)
Notes: # and blank group compare p, and < 0. 05, * and blank group be p < 0. 01 relatively
The motionless state that mice shows in the forced swimming model has reflected the desperate behavior of animal, but the depressive state of simulating human.Can find out from table 3 data; Chinese medicine composition medicinal liquid group of the present invention and blank group more all can be in various degree dead time of shortening forced swimming mice; The dead time of forced swimming mice can be significantly shortened in 2,3,4,5,6,7,8,9,10,11,12 groups of medicinal liquids and the comparison of blank group, has significant difference (p < 0.05).Particularly 3,4,5,8 groups of mice dead times reduce the utmost point significant difference of having compared with the blank group (p < 0.01).
4.3 Chinese medicine composition of the present invention is to the influence of mouse tail suspension dead time
Each is organized mouse tail suspension dead time result and sees table 4.
Table 4 Chinese medicine composition of the present invention is to the influence of mouse tail suspension experiment dead time (x ± s)
Notes: # and blank group compare p, and < 0. 05, * and blank group be p < 0. 01 relatively
The motionless state that mice occurs in outstanding tail model has reflected the desperate behavior of animal, and this is the result who continues the chronic stress sexual stimulus.Can know that by table 42,3,4,5,6,7,8,9,10,11,12 groups of Chinese medicine composition medicinal liquids of the present invention have been compared significant difference (p < 0.05) with the blank group.3,4,5 groups of the Chinese medicine composition medicinal liquids of the present invention utmost point significant difference (p < 0.01) of having compared with the blank group.Special, 3,4,5 groups of Chinese medicine composition medicinal liquids of the present invention have significant difference for 2 groups with positive control, and littler than positive controls good effect, confidence interval, and it is better promptly to reduce the effect of mice dead time than positive controls.
To sum up table 4 data show that the Chinese medicine composition minimizing mice dead time of the present invention is comparatively obvious, demonstrate stronger antidepressant effect.
4.4 Chinese medicine composition of the present invention brings out the influence that mouse temperature changes to reserpine
Experimental result is seen table 5.
Table 5 Chinese medicine composition of the present invention brings out the influence (1) that mouse temperature changes (x ± S) to reserpine
Annotate: behind the 24h, dead 1 of blank group, 8 groups dead 1 of medicinal liquid, 9 groups dead 1 of medicinal liquid, medicinal liquid 10
Organize dead 1,11 groups dead 1 of medicinal liquid.
Can find out that from table 5 body temperature obviously descends in the blank group lumbar injection reserpine 4h, and body temperature behind the 24h
Do not go up.Each group of Chinese medicine composition of the present invention, positive controls have the effect that obvious antagonist relaxing the bowels with purgatives of warm nature falls in 4h, compare with the blank group to have significant difference, and body temperature is replied basically behind 48h.So can think that the present invention can resist reserpine and cause mouse temperature decline.
Can find out that from the pharmacodynamics test of different animal models this Chinese medicine composition all has inhibitory action in various degree to the mice of depression model, with positive control drug quite even be superior to positive control drug.
Chinese medicine composition clinical effectiveness situation of the present invention:
Model case 1: Mrs Wang, 26 years old, puerperal, patient's lather was depressed, often indescribablely feared irritability, nervous.Take capsule of the present invention effect after 3 days every day and manifest gradually, after 14 days, symptom is alleviated fully, follows up a case by regular visits to and does not have recurrence half a year.
Model case 2: Mrs Ma, 28 years old, puerperal, the patient felt that pressure is huge, and life is lost interest, and suicidal thought is arranged, the enthusiasm and the enjoyment of forfeiture work.Take capsule of the present invention effect after 7 days every day and manifest gradually, after 1 month, symptom is alleviated fully, follows up a case by regular visits to and does not have recurrence in 1 year.
Model case 3: Mrs Liu, 25 years old, puerperal patient's lethargy, inappetence feels weak all over, mental instability, when happiness time is sad.Take capsule of the present invention effect after 7 days every day and manifest gradually, after 1 month, symptom is alleviated fully, follows up a case by regular visits to and does not have recurrence in 1 year.
Model case 4: the Ms Zhang, 30 years old, puerperal, the patient produced a kind of helplessness beyond description, worried to support the child who does not live and given birth to, and thinking is inaccessible, many bad dreams, and inappetence loses weight.Take capsule of the present invention effect after 7 days every day and manifest gradually, after 1 month, symptom is alleviated fully, follows up a case by regular visits to and does not have recurrence in 1 year.
Model case 5: the Ms Zhang, 32 years old, puerperal, the patient often was difficult to fall asleep, and had eaten 7 days sleeping pill, and medicine is liked flying into a rage once stopping sleeping not person, and is depressed, often expects committing suiside.Take capsule of the present invention every day and after 7 days, can fall asleep naturally, its effect manifests gradually, and after 1 month, symptom is alleviated fully, follows up a case by regular visits to and does not have recurrence in 1 year.
It is thus clear that the present invention has depressed liver-energy dispersing and QI regulating, clearing heat and relieving fidgetness, astringing QI is calmed the nerves, and along the property of liver, flourish muscle is supported marrow, the stomach function regulating activating the spleen, the effect of benefiting blood and regulating blood circulation is the pure Chinese medicine product of treatment postpartum depression.
The specific embodiment
Below description through the specific embodiment the present invention is described further; But this is not to be limitation of the present invention; Those skilled in the art are according to basic thought of the present invention; Can make various modifications or improvement, but only otherwise break away from basic thought of the present invention, all within scope of the present invention.
Embodiment 1: take by weighing Semen Ziziphi Spinosae 3g, Radix Rehmanniae 2g, Folium Bambusae 1g, Olibanum 0.5g, Radix Angelicae Sinensis 2g, Radix Bupleuri 2g, Radix Linderae 2g, Cortex Albiziae 3g, Squama Manis 0.5g, Rhizoma Chuanxiong 2g, Radix Achyranthis Bidentatae 1g by weight proportion of the present invention; With above-mentioned pulverizing medicinal materials; Cross 80 mesh sieves; Behind ultraviolet-sterilization, insert capsule No. 0, promptly get.
Embodiment 2: take by weighing Semen Ziziphi Spinosae 2g, Radix Rehmanniae 1g, Folium Bambusae 1g, Olibanum 0.5g, Radix Angelicae Sinensis 2g, Radix Bupleuri 1g, Radix Linderae 2g, Cortex Albiziae 2g, Squama Manis 0.5g, Rhizoma Chuanxiong 1g, Radix Achyranthis Bidentatae 1g by weight proportion of the present invention; With above-mentioned pulverizing medicinal materials; Cross 80 mesh sieves; Behind ultraviolet-sterilization, insert capsule No. 0, promptly get.
Embodiment 3: take by weighing Semen Ziziphi Spinosae 3g, Radix Rehmanniae 2g, Folium Bambusae 2g, Olibanum 2g, Radix Angelicae Sinensis 2g, Radix Bupleuri 3g, Radix Linderae 3g, Cortex Albiziae 3g, Squama Manis 1g, Rhizoma Chuanxiong 2g, Radix Achyranthis Bidentatae 2g by weight proportion of the present invention; With above-mentioned pulverizing medicinal materials, cross 80 mesh sieves, behind ultraviolet-sterilization; Insert capsule No. 0, promptly get.
Embodiment 4: take by weighing Semen Ziziphi Spinosae 2.5g, Radix Rehmanniae 2g, Folium Bambusae 1.5g, Olibanum 1g, Radix Angelicae Sinensis 2.5g, Radix Bupleuri 2g, Radix Linderae 2.5g, Cortex Albiziae 3g, Squama Manis 0.5g, Rhizoma Chuanxiong 2g, Radix Achyranthis Bidentatae 1g by weight proportion of the present invention; With above-mentioned pulverizing medicinal materials; Cross 80 mesh sieves; Behind ultraviolet-sterilization, insert capsule No. 0, promptly get.
Embodiment 5: take by weighing Semen Ziziphi Spinosae 2.5g, Radix Rehmanniae 1g, Folium Bambusae 1.5g, Olibanum 1g, Radix Angelicae Sinensis 2g, Radix Bupleuri 1g, Radix Linderae 2g, Cortex Albiziae 2g, Squama Manis 0.5g, Rhizoma Chuanxiong 1g, Radix Achyranthis Bidentatae 2g by weight proportion of the present invention; With above-mentioned pulverizing medicinal materials; Cross 80 mesh sieves; Behind ultraviolet-sterilization, insert capsule No. 0, promptly get.
Claims (4)
1. a Chinese medicine composition of treating postpartum depression is characterized in that being processed by the raw material of following weight portion: Semen Ziziphi Spinosae 2-3 part, Radix Rehmanniae 1-2 part, Folium Bambusae 1-2 part, Olibanum 0.5-2 part, Radix Angelicae Sinensis 2-3 part, Radix Bupleuri 1-3 part, Radix Linderae 2-3 part, Cortex Albiziae 2-3 part, Squama Manis 0.5-1 part, Rhizoma Chuanxiong 1-2 part, Radix Achyranthis Bidentatae 1-2 part.
2. like the Chinese medicine composition of the described treatment postpartum depression of claim l, it is characterized in that processing: 3 parts of Semen Ziziphi Spinosaes, 2 parts of Radix Rehmanniae, 1 part on Folium Bambusae, 0.5 part of Olibanum, 2 parts of Radix Angelicae Sinensis, 2 parts of Radix Bupleuri, 2 parts of the Radixs Linderae, 3 parts of Cortex Albiziaes, 0.5 part of Squama Manis, 2 parts of Rhizoma Chuanxiongs, 1 part of Radix Achyranthis Bidentatae by the raw material of following weight portion.
3. the Chinese medicine composition of treatment postpartum depression as claimed in claim 2 is characterized in that: said Chinese medicine composition is a peroral dosage form.
4. the Chinese medicine composition of treatment postpartum depression as claimed in claim 3 is characterized in that: said Chinese medicine composition peroral dosage form is a capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101199831A CN102614407B (en) | 2012-04-24 | 2012-04-24 | Chinese medicinal composition for treating postpartum depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101199831A CN102614407B (en) | 2012-04-24 | 2012-04-24 | Chinese medicinal composition for treating postpartum depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102614407A true CN102614407A (en) | 2012-08-01 |
| CN102614407B CN102614407B (en) | 2013-07-24 |
Family
ID=46554855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101199831A Active CN102614407B (en) | 2012-04-24 | 2012-04-24 | Chinese medicinal composition for treating postpartum depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102614407B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306797A (en) * | 2014-11-21 | 2015-01-28 | 鹿树军 | Traditional Chinese medicine combination for treating postnatal depression |
| CN105148100A (en) * | 2015-10-27 | 2015-12-16 | 程宝英 | Nursing capsules for treating postpartum depression and preparation method thereof |
| CN105998835A (en) * | 2016-07-09 | 2016-10-12 | 徐德玲 | Drug for treating postnatal depression and preparation method |
| CN105999148A (en) * | 2016-06-03 | 2016-10-12 | 南阳医学高等专科学校 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
| JP2018516995A (en) * | 2015-06-10 | 2018-06-28 | ディスハーブ ヘルス ピーティーワイ リミテッドＴｈｉｓｈｅｒｂ Ｈｅａｌｔｈ Ｐｔｙ Ｌｔｄ | Pharmaceutical composition for the treatment of depression and method for its preparation |
| CN115350226A (en) * | 2022-09-14 | 2022-11-18 | 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) | Traditional Chinese medicine mixture for treating postpartum depression and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1682989A (en) * | 2005-02-21 | 2005-10-19 | 李有田 | Chinese medicine for treating depression |
| CN1709459A (en) * | 2005-07-11 | 2005-12-21 | 杨永信 | Chinese medicine for treating depression |
| CN101711809A (en) * | 2009-05-08 | 2010-05-26 | 成都中医药大学附属医院 | Medicine composition for treating postpartum melancholia, preparation method and application |
-
2012
- 2012-04-24 CN CN2012101199831A patent/CN102614407B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1682989A (en) * | 2005-02-21 | 2005-10-19 | 李有田 | Chinese medicine for treating depression |
| CN1709459A (en) * | 2005-07-11 | 2005-12-21 | 杨永信 | Chinese medicine for treating depression |
| CN101711809A (en) * | 2009-05-08 | 2010-05-26 | 成都中医药大学附属医院 | Medicine composition for treating postpartum melancholia, preparation method and application |
Non-Patent Citations (3)
| Title |
|---|
| 徐治国等: "《中药学》", 30 April 2007, 四川科学技术出版社 * |
| 施国惠: "产后抑郁症中药治疗研究现状", 《现代诊断与治疗》 * |
| 项平等: "《中药大辞典》", 31 March 2006, 上海科学技术出版社 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306797A (en) * | 2014-11-21 | 2015-01-28 | 鹿树军 | Traditional Chinese medicine combination for treating postnatal depression |
| JP2018516995A (en) * | 2015-06-10 | 2018-06-28 | ディスハーブ ヘルス ピーティーワイ リミテッドＴｈｉｓｈｅｒｂ Ｈｅａｌｔｈ Ｐｔｙ Ｌｔｄ | Pharmaceutical composition for the treatment of depression and method for its preparation |
| CN105148100A (en) * | 2015-10-27 | 2015-12-16 | 程宝英 | Nursing capsules for treating postpartum depression and preparation method thereof |
| CN105999148A (en) * | 2016-06-03 | 2016-10-12 | 南阳医学高等专科学校 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
| CN105998835A (en) * | 2016-07-09 | 2016-10-12 | 徐德玲 | Drug for treating postnatal depression and preparation method |
| CN115350226A (en) * | 2022-09-14 | 2022-11-18 | 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) | Traditional Chinese medicine mixture for treating postpartum depression and application thereof |
| CN115350226B (en) * | 2022-09-14 | 2023-05-23 | 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) | Traditional Chinese medicine mixture for treating postpartum depression and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102614407B (en) | 2013-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101322830B (en) | Medicament for treating postpartum depression and preparation method thereof | |
| CN102614407B (en) | Chinese medicinal composition for treating postpartum depression | |
| CN104490191A (en) | Traditional Chinese medicine pillow for treating vertigo after brain surgical operation or intracranial tumor operation | |
| CN100548352C (en) | A kind of Chinese medicine composition of orally taken for curing depression | |
| CN104663989A (en) | Soothing tea and preparation method thereof | |
| CN104338050A (en) | Health care product capable of improving sleep quality | |
| CN104642678A (en) | Female beauty tranquilizing tea and preparation method thereof | |
| CN104888152A (en) | Traditional Chinese medicine preparation for treating postpartum depression and preparation method therefor | |
| CN102908396B (en) | Chinese medicinal composition for promoting sleeping and preparation method thereof | |
| CN104800553B (en) | A kind of Chinese medicine composition for treating climacteric insomnia disease and preparation method thereof | |
| CN103202964B (en) | Brain-improving and mind-calming medicinal liquor | |
| CN101129806A (en) | Orally taken traditional Chinese medicine composition for treating melancholia | |
| CN104547642A (en) | Tradtional Chinese medicine composition for treating female fibromyalgia syndromes | |
| CN104547556A (en) | Traditional Chinese medicine preparation for treating pediatric epilepsy and preparation method thereof | |
| CN104383449B (en) | Pharmaceutical composition for treating depression syndrome | |
| CN104840794B (en) | A kind of Chinese medicine composition for treating senile insomnia and preparation method thereof | |
| CN103861075A (en) | Traditional Chinese medicine for treating insomnia and preparation method thereof | |
| CN108524861A (en) | A kind of traditional Chinese medicinal ointment and preparation method thereof for treating insomnia | |
| CN105435083A (en) | Capsule for postnatal depression | |
| CN105456955A (en) | Medicine preparation for treating depressive disorder and application thereof | |
| CN105232709A (en) | Method for preparing traditional Chinese medicine combination treating postpartum depression | |
| CN105381341A (en) | Pharmaceutical composition for treating insomnia and preparation method thereof | |
| CN103816467A (en) | Traditional Chinese medicine for treating insomnia with insufficiency of heart and spleen | |
| CN104800761B (en) | A kind of Chinese medicine composition for the treatment of postpartum depression | |
| CN104688855A (en) | Coptidis rhizome and donkey-hide glue composition for the treatment of chronic fatigue syndrome and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: CUI XINMING Free format text: FORMER OWNER: XU CONGYU Effective date: 20130327 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130327 Address after: 266200, No. seven, 179 village, Wenquan Town, Jimo, Shandong, Qingdao Applicant after: Cui Xinming Address before: 276017 A302 building, Linyi hi tech Industrial Development Zone, Shandong, China Applicant before: Xu Congyu |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIDONG SANJIANG CONSTRUCTION MACHINERY CO., LTD. Free format text: FORMER OWNER: CUI XINMING Effective date: 20140728 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140728 Address after: 226200 Nanhai Road, Binhai Industrial Park, Nantong, Jiangsu, Qidong Patentee after: Qidong Sanjiang Construction Machinery Co., Ltd. Address before: 266200, No. seven, 179 village, Wenquan Town, Jimo, Shandong, Qingdao Patentee before: Cui Xinming |